Prediction and reasons for COVID-19 second dose vaccine hesitation: a cross-sectional study in a municipality of Brazil

• Autor(a) principal: Sartorão-Filho,Carlos Izaias
• Data de Publicação: 2022
• Outros Autores: Zoqui,Mariana Costa, Duarte,Douglas Otomo, Ribeiro,Edy Alyson, Bisetto,Vinicius César Queiroz, Cachoni,Lara Escobar Gavião, Sartorão,Ana Luísa Varrone, Terribile,Diogo Coutinho, Mello,Beatriz Balsimelli de, Sartorão-Neto,Carlos Izaias, Mello,Roberto de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: São Paulo medical journal (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802022005021219
• topic: COVID-19; Vaccination hesitancy; Vaccination; Vaccination refusal; Anti-vaccination movement; Coronavirus disease 19; Immunization, active; Anti-vaccine groups

ABSTRACT BACKGROUND: Hesitation and refusal to take a second dose of the vaccine for coronavirus disease 19 (COVID-19) are prevalent. OBJECTIVES: We aimed to identify predictive factors for hesitation or refusal and describe groups with higher rates of vaccine hesitancy. DESIGN AND SETTING: A cross-sectional study in Assis City, Brazil. METHODS: The study included adults who passed the due date for taking the COVID-19 second dose vaccine. Participants were recruited in December 2021 using a mobile-based text message. Sociodemographic and clinical data and reasons for hesitance were collected. The outcome was the attitude towards completing the recommended second dose of the vaccine. Bivariate and multivariate Poisson analyses were performed to determine the adjusted predictors. RESULTS: Participants between 30–44 years of age had a 2.41 times higher prevalence of hesitation than those aged 18–29 years. In addition, people who had adverse events or previously had COVID-19 had 4.7 and 5.4 times higher prevalences of hesitation, respectively (P value < 0.05). CONCLUSION: We found a significant group of adults aged between 30–44 years who refused the second dose of the COVID-19 vaccine. Furthermore, those who reported adverse effects after the first dose and those who had COVID-19 previously were a significant group for refusal.